Published Research
Peer-reviewed studies from NIH PubMed on compounds available through BioReceptor Labs. All citations link directly to PubMed for full-text access. We present research — we do not make medical claims.
BPC-157
4 published studiesMultifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
PMID 40005999BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders. Unlike many other drugs, BPC 157 has a desirable safety p…
Read Full Paper on PubMed →Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
PMID 30915550There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factor…
Read Full Paper on PubMed →Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
PMID 40756949Background: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. Preclinical studies show its potential for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries. Despite lacking US Food and Drug Administration…
Read Full Paper on PubMed →Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
PMID 34267654Significance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed, focusing on the particular skin wound therapy, incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, which may be generali…
Read Full Paper on PubMed →Thymosin Beta-4 (TB-500)
4 published studiesThymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
PMID 22074294Thymosin β(4), a low molecular weight, naturally-occurring peptide plays a vital role in the repair and regeneration of injured cells and tissues. After injury, thymosin β(4), is released by platelets, macrophages and many other cell types to protect cells and tissues from further damage and reduce apoptosis, inflammation and microbial growth. Thym…
Read Full Paper on PubMed →beta-Thymosins.
PMID 17468232The development of thymosin beta(4) from a thymic hormone to an actin-sequestering peptide and back to a cytokine supporting wound healing will be outlined. Thymosin fraction 5 consists of a mixture of polypeptides and improves immune response. Starting with fraction 5, several main peptides (thymosin alpha(1), polypeptide beta(1), and thymosin bet…
Read Full Paper on PubMed →Thymosin beta-4 – A potential tool in healing middle ear lesions in adult mammals.
PMID 38706788Acute tympanic membrane perforations primarily occur due to injury or infection in humans. In acute cases, nearly 80-94 % of the perforations heal spontaneously. In chronic cases, non-surgical treatment becomes significantly limited, and the perforation can be restored only by myringoplasty. In addition to classical grafts such as the fascia or car…
Read Full Paper on PubMed →Thymosin beta-4 participate in antibacterial immunity and wound healing in black tiger shrimp, Penaeus monodon.
PMID 37689229Thymosin beta-4 (Tβ4) is a ubiquitous protein with multiple and diverse intracellular and extracellular functions in vertebrates, which play fundamental roles in innate immune against pathogens and wound healing. In this study, the full-length cDNA of Tβ4 was cloned from Penaeus monodon (designated as PmTβ4), using the technology of rapid amplifica…
Read Full Paper on PubMed →Ipamorelin
4 published studiesThe growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced body mass reduction in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
PMID 39043357This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate body mass reduction and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field stimulation (EFS)-induced contractions of isolated ferret ileum was compared …
Read Full Paper on PubMed →Ipamorelin, the first selective growth hormone secretagogue.
PMID 9849822The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds la…
Read Full Paper on PubMed →The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.
PMID 11735244The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were administered via subcutaneous route for 3 months with GC (methylprednisolone) 9 mg/kg/day or GHS (Ipamorelin) 100 microg/kg…
Read Full Paper on PubMed →Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.
PMID 12168778Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells. Secretion is regulated by growth hormone releasing hormone (GHRH) and somatostatin. Morever, GH secretagogues (GHS) can exert a considerable effect on GH secretion. In order to determine the effects of chronic treatment with the GHS Ipamorelin on the compositi…
Read Full Paper on PubMed →AOD-9604
3 published studiesIncrease of fat oxidation and body mass reduction in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
PMID 11673763To observe the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on body weight, energy balance, and substrate oxidation rates in obese (ob/ob) and lean C57BL/6Jmice. In vitro assays were used to confirm whether the effects of AOD9604 are mediated through the hGH receptor, and if this peptide is capable of cel…
Read Full Paper on PubMed →Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
PMID 11146367A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. Daily treatment with an oral dose of AOD9604 of 500 microg/kg body weight for 19 days reduced over 50% (15.8 +/- 0.6 vs. 35.6 +/- 0.8 g) body weight gain of the animals in comparison with the control….
Read Full Paper on PubMed →The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
PMID 11713213Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing body mass reduction and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with the beta-adrenergic pathway, particularly with the beta(3)-adrenergic receptors (b…
Read Full Paper on PubMed →All research sourced from NIH National Library of Medicine
pubmed.ncbi.nlm.nih.govBioReceptor Labs presents published research for educational purposes only. We do not claim our products treat, cure, or prevent any disease. All products are for research use only.
